Compare GLRE & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GLRE | TECX |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | Cayman Islands | United States |
| Employees | N/A | 60 |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.9M | 549.5M |
| IPO Year | 2007 | N/A |
| Metric | GLRE | TECX |
|---|---|---|
| Price | $17.19 | $32.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $75.20 |
| AVG Volume (30 Days) | 169.3K | ★ 184.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.03 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $14.39 |
| 52 Week High | $19.39 | $39.53 |
| Indicator | GLRE | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 49.53 |
| Support Level | $16.90 | $27.31 |
| Resistance Level | $18.11 | $35.99 |
| Average True Range (ATR) | 0.51 | 2.79 |
| MACD | 0.08 | -0.46 |
| Stochastic Oscillator | 93.55 | 23.21 |
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.